| |
Pregnancy and Lyme disease
Written by John Drulle, M.D. in December, 1990 and reprinted with permission by
the John Drulle, MD Memorial Lyme Fund, Inc. in 2006.
When a pregnant woman is infected with Lyme disease, not only is she subject to
its devastation, but her baby is too. At this time there is only a small amount
of information available in the medical literature. I will review the major
articles, and after describing our own experiences with Lyme and pregnancy,
present what I feel is a rational approach to this issue.
The first case of transplacental passage of Borrelia burgdorferi was reported in
1985 in Wisconsin by Schlesinger. The woman was bitten during her first
trimester and developed an EM rash with two satellite lesions. This was followed
by typical Lyme symptoms. She did not receive medical treatment as Lyme was not
diagnosed at the time. She delivered a male baby at 35 weeks. The baby died 39
hours later from congestive heart failure, and at autopsy there were several
major defects of the heart. Spirochetes were found in the spleen, kidneys, bone
marrow and the heart. The mother tested positive for Lyme. Here we can only
speculate that the Lyme might have been responsible for the birth defects, as
these same types of problems can occur in non-Lyme situations.
In 1987, Dr. Alan MacDonald reported a case of a woman infected with Lyme in her
first trimester of pregnancy, which unfortunately was not diagnosed or treated.
She had developed a circular red rash which was followed by painful swelling of
her knee. These resolved spontaneously. The woman went into labor at term, and
delivered a 2,500 gram stillborn baby. Autopsy revealed a ventricular septal
defect, i.e. a hole in the wall of the heart which separates the two main
pumping chambers. The Lyme bacterium was cultured from the baby’s liver, and it
was demonstrated in the brain, heart, adrenal gland and the placenta. The
mother’s blood tested positive for antibodies to the Lyme spirochete and
negative for syphilis. Dr. MacDonald reported three other cases of fetal death
in the second trimester, in which the Lyme spirochete was cultured from the
livers. None of the mothers gave any history suggesting Lyme infection.
In 1986, Weber reported a case of Lyme infection in a newborn baby. The mother
had been bitten by multiple ticks during her first trimester. She developed an
EM rash several weeks later. She was treated with a “standard” course of oral
penicillin for seven days, three times a day. The baby was delivered at term and
appeared normal. During the next 23 hours the baby developed breathing problems
and died. Autopsy showed brain hemorrhages. Spirochetes compatible with Borrelia
burgdorferi, the Lyme spirochete, were demonstrated in the brain and the liver.
Initial testing of the mother’s blood was negative for antibodies to the Lyme
spirochete; however, at a later date her frozen blood tested positive for IgM
antibodies by the ELISA test.
Markowitz published a study of Lyme and pregnancy in 1986. He described nineteen
patients who were infected during pregnancy. Five of these had adverse outcomes
(one fetal death at 20 weeks, high bilirubin level in a four-week premature
baby, webbed toes, blindness and developmental delay, and a newborn rash).
Thirteen of the nineteen had received antibiotics. The authors concluded that
there was no proof that Lyme was responsible for the adverse outcomes since all
of them were dissimilar. However, there was a consensus that this was an
abnormally high frequency of adverse outcomes, and that pregnant women with
diagnosed Lyme should be treated immediately with penicillin.
Williams and colleagues conducted a study in a Lyme-endemic area in New York of
umbilical cord blood. Of 255 infants tested, 10.2% had detectable antibody to
the Lyme spirochete. Of 166 infants born in a non-endemic area, 2.4% had
detectable antibodies. The rate of birth defects did not differ significantly
between the two groups; however, the first group tended to be of lower birth
weight and smaller for their gestational age, and tended to have more jaundice.
The authors concluded that these differences were not significantly different. A
glaring flaw in this study is that it only included live births. Since
miscarriages, stillbirth and perinatal infant deaths were not included, the
possibility of congenital defects possibly associated with Lyme and incompatible
with life are not included. Therefore, the author’s contention that no
association exists between gestational Lyme and congenital defects should be
viewed with skepticism.
Dr. Andrea Dlesk, of the Marshfield clinic in Wisconsin, studied 143 healthy
pregnant women. Lyme serologic tests were obtained on the initial and postpartum
visits. At the time the data were reported, 116 women had completed their
pregnancies and 12 had miscarried, one of whom tested positive. Of the 104 women
who did not miscarry, 13 women tested positive for Lyme. The conclusion was that
healthy women who test positive for Lyme are at no increased risk for
miscarriage. Again this study is flawed in that there are no autopsy data on the
12 miscarriages. It is quite possible that, in the 11 seronegative mothers who
miscarried, seronegative Lyme was present and may have caused defective fetuses.
Seronegative Lyme is a real entity and nay account for 25% of all cases of Lyme.
In 1988, Carlomango studied 49 women who had either a 1st or 2nd trimester
spontaneous abortion. Six (6) of them (12.2%) tested positive, compared to 3 of
49 women who delivered at term. The authors concluded that there was no
statistical significance between the two groups.
In 1988, Nadal surveyed 1,416 women and their 1,434 infants at delivery for
presence of antibodies to the Lyme spirochete. Twelve women tested positive
(only one had a history compatible with EM during pregnancy), six had a history
of pre-existing Lyme and five had unremarkable histories. Of these twelve women,
seven had remarkable outcomes:
1. Two had elevated bilirubinemia
2. One had muscle hypotonia (laxness)
3. One was post-term, small for age, and evidenced chronic placental
insufficiency
4. One had transient macrocephaly (large head)
5. One had transient supraventricular extrasystoles (“skipped heart beats”)
6. The infant born of the mother with EM had a VSD-hole in the heart connecting
the two main pumping chambers.
Since none of these babies had positive blood tests for antibodies to Lyme, the
conclusion was that the adverse outcomes were not due to Lyme. The major flaw in
this conclusion is the assumption that congenital Lyme babies are seropositive.
This has been refuted by the work of Dr. Alan MacDonald, and is analogous to the
findings of seronegativity in congenital syphilis.
In 1989, Dr. Alan MacDonald reported his findings in autopsies performed
following perinatal deaths at Southhampton Hospital between 1978 and 1988. It
must be noted that routine pathology studies on tissues will not demonstrate the
Lyme spirochete. Unless there is a high index of suspicion for Lyme disease, the
special silver or immunologic stains which can identify the spirochete are not
used. He also reports four cases where there was live birth and spirochetes were
demonstrated in the placentas. In the group of perinatal deaths there was no
history or evidence of Lyme disease in the mothers. Their blood tests were
negative in all but one case. Spirochetes compatible with Borrelia burgdorferi
were identified in the vital organs and numerous developmental defects were
observed. Dr. MacDonald’s conclusions are:
1. Tissue inflammation is not seen in fetuses with transplacentally acquired
infection with the Lyme spirochete.
2. Lyme disease acquired in utero may result in fetal death in utero, fetal
death at term or infant death after birth. Babies may also survive in spite of
the bacteria being isolated in the placenta.
3. In all but one of these cases where the Lyme organism was identified in the
placenta or the fetal tissues, the maternal blood had no evidence of antibodies
to the Lyme bacteria. In only two of the fourteen cases was there a maternal
history compatible with Lyme disease, yet neither of the two were serologically
confirmed.
This is the extent of the currently available information on Lyme and Pregnancy
in the medical literature in 1990. Comparing the various studies have led us to
arrive at the following conclusions:
1. Lyme disease is a serious threat to pregnant women in that it may cause fetal
damage and death.
2. Pregnancy may mask symptoms of Lyme in the mother and may result in
seronegativity.
3. Serologic screening of pregnant women in highly endemic areas is not
recommended.
4. Pregnant women who test positive for Lyme antibodies, yet have no symptoms
suggesting active Lyme, are probably at a lower risk of passing the infection
across the placenta. It may be possible that the presence of antibody prevents
the Borrelia burgdorferi from crossing the placenta.
5. Babies born with Lyme disease can be expected to have a negative blood test
for Lyme antibodies. Few have positive test.
6. We desperately need a better test for detecting Lyme in pregnant women. It is
clear that serologies are inadequate. Efforts should be directed at evaluating
urine antigen and PCR testing in pregnancy and in neonates.
In our practice we have seen several dozen pregnant women with Lyme disease. I
feel that a much more aggressive approach must be taken with them than with
non-pregnant patients. It is preferable to err on the side of overtreatment than
undertreatment, especially since the antibiotics we use have not been associated
with birth defects or adverse effects on the developing fetus. These are general
recommendations that we have developed over the last three years:
A pregnant woman who presents with a deer tick bite in an endemic area for Lyme
disease is treated as if she had Stage 1 Lyme disease. We would treat with one
to two months of oral antibiotics, such as Amoxicillin or Ceftin. (Tetracycline
and Doxycycline are contraindicated in pregnancy.)
A pregnant woman with an EM rash should receive three to four weeks of
intravenous Claforan, Rocephin or aqueous penicillin. We have evidence that even
without constitutional symptoms the Lyme spirochete may have spread throughout
the mother’s body by the fifth day after an infected tick bite. As noted above,
treatment failure with oral penicillin has been reported.
Pregnant women who are diagnosed as having Lyme by symptoms and blood tests, who
do not have a clear history of a tick bite or EM rash, and have not yet been
treated, should be treated with intravenous antibiotics. Here, since the length
of infection is unknown, we must assume that the spirochetes have spread
throughout the mother’s body. It has generally been assumed that it is only
possible to culture the Lyme spirochete from the blood only in the early stages
of Lyme disease, so that a woman in the later stages of Lyme is safe from having
blood-borne spirochetes reaching and crossing the placenta to the fetus. Yet
unpublished data suggests that blood drawn from chronic Lyme patients during the
afternoon, when they usually spike a mild fever, may yield spirochetes, using a
specially modified BS Kelly culture Medium. Animal studies with chronically
infected dogs show that when their immune systems are suppressed by injecting
them with dexamethasone, a steroid similar to prednisone, it is possible to
culture the Lyme spirochete from their blood the day after the injection. It may
be possible that the state of pregnancy, which is also immunosuppressive, may
induce the spirochete to enter the bloodstream and reach the placenta.
We recommend that pregnant women with active Lyme, or a history of treated Lyme,
have monthly urine antigen tests for Lyme until the seventh month of pregnancy.
There is some evidence that during the 3rd trimester, false positive urine tests
may occur.
When the baby is delivered, we recommend that the placenta be examined for
spirochetes. If spirochetes are demonstrated in the placenta, the baby should be
treated with intravenous antibiotics.
I must again stress that these are guidelines that we use in our own practice. I
realize that many physicians might criticize them fro being an over-reaction and
too aggressive: however, I have seen a number of babies born with congenital
Lyme, and am quite aware of the devastating effects it can cause. Following the
recommendations I’ve outlined above, we have had normal outcomes in all the
pregnant women whom we have treated.
Written by John Drulle, M.D. in December, 1990 and reprinted with permission by
the John Drulle, MD Memorial Lyme Fund, Inc. in 2006. | |
.
|